Abstract: The invention relates provides a novel crystal structure of the fibrillogenic part of amyloid ?-peptide (A?). More specifically the crystal structure is A?-IgNAR and, accordingly the present invention also relates to selecting and/or designing compounds that modulate amyloid ?-peptide (A?) activity using techniques such as in silico screening and crystal soaking experiments. The invention further relates to compounds and methods for inhibiting interaction between amyloid ?-peptide (A?) monomers, more particularly, inhibiting or disrupting amyloid ?-peptide (A?) oligomer formation and toxic activity.

Abstract: The invention relates provides a novel crystal structure of the fibrillogenic part of amyloid ?-peptide (A?). More specifically the crystal structure is A?-IgNAR and, accordingly the present invention also relates to selecting and/or designing compounds that modulate amyloid ?-peptide (A?) activity using techniques such as in silico screening and crystal soaking experiments. The invention further relates to compounds and methods for inhibiting interaction between amyloid ?-peptide (A?) monomers, more particularly, inhibiting or disrupting amyloid ?-peptide (A?) oligomer formation and toxic activity.

Abstract: The invention relates provides a novel crystal structure of the fibrillogenic part of amyloid ?-peptide (A?). More specifically the crystal structure is A?-IgNAR and, accordingly the present invention also relates to selecting and/or designing compounds that modulate amyloid ?-peptide (A?) activity using techniques such as in silico screening and crystal soaking experiments. The invention further relates to compounds and methods for inhibiting interaction between amyloid ?-peptide (A?) monomers, more particularly, inhibiting or disrupting amyloid ?-peptide (A?) oligomer formation and toxic activity.